Please login to the form below
hyperkalaemia
This page shows the latest hyperkalaemia news and features for those working in and with pharma, biotech and healthcare.
NICE says no to AZ and Vifor’s rival hyperkalaemia drugs
Between 1% and 10% of hospital inpatients have hyperkalaemia. Many patients won’t display any symptoms, but some severe cases can lead to cardiac arrest. ... Hyperkalaemia is also seen in patients taking common medications for heart failure, such as
Latest news
-
AZ gets US approval for Veltassa rival Lokelma
But GlobalData predicts Veltassa has the edge due to positive data in chronic hyperkalaemia. ... AstraZeneca has picked up FDA approval for its hyperkalaemia treatment Lokelma, allowing it to compete head-to-head with rival Vifor Pharma on both sides of
-
Daily Brief: AI to boost early NHS cancer diagnosis, AZ shareholder revolt, Juluca approval
The company has a number of promising new cancer treatments, and has just received FDA approval for the delayed hyperkalaemia drug Lokelma.
-
AZ finally gets EU nod for Veltassa rival Lokelma
And expects a US FDA verdict for the hyperkalaemia treatment later this year. ... The approval of Lokelma “addresses a significant unmet need by bringing a rapid and sustained therapeutic option for patients with hyperkalaemia,” she added.
-
Vifor wins European approval for Veltassa
European Commission approves the drug to treat hyperkalaemia. The European Commission (EC) has approved Vifor’s Veltassa (patiromer) to treat adults with hyperkalaemia, a potentially life threatening condition which can cause ... The European
-
FDA turns down AZ's ZS-9 once again on manufacturing issues
The US regulator issued a Complete Response Letter to ZS Pharma regarding its application for ZS-9 (sodium zirconium cyclosilicate) as a treatment for the condition - known as hyperkalaemia - after an ... Veltassa was launched in early 2016 - becoming
More from news
Approximately 5 fully matching, plus 8 partially matching documents found.
Latest Intelligence
-
Deal Watch July 2016
for the treatment of hyperkalaemia.
-
Deal Watch November 2015
Paying $90 per share (headline value $2.7bn) in acquiring ZS Pharma, AstraZeneca gains access to ZS-9, a possible best in class product for hyperkalaemia which is under FDA review. ... ZS Pharma. AstraZeneca. Acquisition - company. Lead product ZS-9,
-
Pharma deals during October 2013
Examples of recent IPOS. Company. Product/technology. Target ($m). Relypsa. Patiromer for hyperkalaemia in chronic kidney disease (phase III).
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Featured jobs
-
Account Director – UK Office
-
Excellent salary and benefits
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
- Account Director, Healthcare Communications
-
Salary TBC
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
Subscribe to our email news alerts
- AZ, Merck’s Lynparza scores market-expanding clinical success
- Moving annual total (MAT)
- Roche undercuts price of Bayer cancer drug after winning FDA approval
- Leaked no-deal Brexit document forecasts widespread shortages
- FDA rejects Sarepta’s new Duchenne drug over safety fears
- Novo Nordisk shareholder revolt reaches Europe
- AstraZeneca buys FDA priority review voucher from Sobi
- Behaviour change – is there something missing?
- BeiGene gets speedy US review for lymphoma drug zanubrutinib
- NICE’s long-serving chief exec Sir Andrew Dillon to step down
- Pfizer goes big on gene therapy with $500m facility spend
- Empowered patients: shaking the foundations of healthcare
PMHub
Star
We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...
Latest intelligence
- Empowered patients: shaking the foundations of healthcare
- Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
- A uniquely English genomic medicine service
- The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
- Blended Intelligence
- Data is the most valued commodity of the modern world. For P&P it's all about the application....
Quick links
Infographics
